Patients experiencing financial distress as a side-effect of cancer are not only reported in the
United States, but also in third-party payer healthcare systems in Europe. Since validated …

Lung diseases carry a significant burden of morbidity and mortality worldwide. The advent of
digital pathology (DP) and an increase in computational power have led to the development …

Molecular and immune therapies have revolutionized cancer treatment and improved
patient outcomes and survival. However, the pricing of these drugs has become an issue as …

Purpose: Because of the escalating cost of cancer care coupled with high insurance
deductibles, premiums, and uninsured populations, patients with cancer are affected by …

Purpose In the past decade, there has been an increase in the development and use of oral
anti-cancer medications (OAMs), especially for breast cancer–the most prevalent cancer in …

Purpose Racial variation in the financial impact of cancer may contribute to observed
differences in the use of guideline-recommended treatments. We describe racial differences …

Simple Summary For cancer patients, many different reasons can cause financial burdens
and economic threads. Sociodemographic factors, rural/remote location and income are …

We commend Dr. Zafar for continuing to highlight the critical issue of financial toxicity in
cancer care and the call to action for the development of interventions to minimize the …

PURPOSE: Patients with hematologic malignancies are extremely vulnerable to financial
toxicity (FT) because of the high costs of treatment and health care utilization. This pilot study …

Background Cancer costs should be discussed by patients and providers, but information is
not readily available. Results from recently published studies (in the last 5 years) on direct …